Home > Dermatology > PFGC 2021 > Psoriasis Therapy: New Findings > Tapering biologics: No alarming signs of increased anti-drug antibodies

Tapering biologics: No alarming signs of increased anti-drug antibodies

Presented By
Dr Juul van den Reek , Radboudumc, the Netherlands
Conference
PFGC 2021
Trial
Phase 4, CONDOR
The induction of antibody formation is one of the major concerns with tapering biologic treatments. However, a CONDOR sub-study found no signs of increased antibody formation after dose reductions of adalimumab or ustekinumab. In patients with long-term use of biologics and stable treatment response, the question often arises of a possible dose reduction. “In a recent questionnaire study that we performed with the International Psoriasis Council, we found that 70% of psoriasis experts already perform dose reductions,” Dr Juul van den Reek (Radboud University Medical Center, the Netherlands) said [1]. The main reasons for doing so were the implicated reduction of costs (87%) and increased patient safety (43%), as well as requests by the patients themselves (41%). Those who chose not to reduce dosages were concerned about the lack of evidence (94%), psoriasis exacerbations (56%), and immunogenicity issues in terms of anti-drug antibodies (53%). The ph...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on